Scientific Publications
Explore Thryv Therapeutics' scientific publications, alongside select reference publications from the broader scientific community. Our research is focused on advancing the understanding and treatment of cardiac arrhythmias and cardiometabolic disorders through selective SGK1 inhibition. We are contributing high-quality scientific evidence — from preclinical mechanism to clinical translation — that supports SGK1 inhibition as a precision approach to inherited and acquired disease.
New in JACC: Heart Failure!
Genetic, Preclinical, and Clinical Evidence Supports SGK1 Inhibition in Heart Failure · Open access, September 2026
Coming soon in JACC: Basic to Translational Science
A Novel SGK1 Inhibitor Prevents Obesity-Related Atrial Fibrillation · Details to be announced soon
Long QT Syndrome Publications
Our Publications
-
EP Europace (May 2023)
-
Heart Rhythm (April 2023)
-
Heart Rhythm O2 (February 2023)
-
European Heart Journal (November 2025)
-
Pharmacological Research (May 2026)
Reference Publications
-
Scientific Reports (March 2017)
-
New England Journal of Medicine (May 2003)
-
Scientific Reports (February 2000)
-
JACC Journals (June 2003)
Inherited and Acquired Cardiomyopathies and Arrhythmias
Our Publications
-
JACC: Heart Failure (September 2026)
-
Sciety (November 2025)
-
Pharmacological Research (October 2024)
-
Journal of Clinical Medicine (September 2023)
-
JACC Journals (January 2026)
-
Circulation (April 2003)
Atrial Fibrillation Publications
Our Publications
-
Circulation (November 2023)
Reference Publications
-
JCI Insight (August 2022)